Liver Diseases
Welcome,         Profile    Billing    Logout  
 309 Companies   473 Products   473 Products   224 Mechanisms of Action   25 Trials   4900 News 


«12345678910111213...9899»
  • ||||||||||  Trial primary completion date:  Individualized Stereotactic Body Radiotherapy of Liver Metastases (clinicaltrials.gov) -  Jul 13, 2017   
    P2,  N=92, Active, not recruiting, 
    Enrolling by invitation --> Active, not recruiting | N=500 --> 241 | Trial primary completion date: Sep 2019 --> Jul 2017 Trial primary completion date: Jan 2017 --> Jan 2016
  • ||||||||||  Inlyta (axitinib) / Pfizer
    Trial primary completion date:  Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib (clinicaltrials.gov) -  Jul 7, 2017   
    P2,  N=50, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017 Trial primary completion date: May 2017 --> May 2018
  • ||||||||||  sorafenib / Generic mfg.
    Trial primary completion date:  Sorafenib for Hepatopulmonary Syndrome (clinicaltrials.gov) -  Jul 6, 2017   
    P2,  N=30, Recruiting, 
    Trial primary completion date: May 2017 --> May 2018 Trial primary completion date: Jun 2017 --> Jun 2018
  • ||||||||||  Trial initiation date:  Study for Consolidation Period of Chronic Hepatitis B (clinicaltrials.gov) -  Jul 6, 2017   
    P=N/A,  N=137, Not yet recruiting, 
    Trial primary completion date: Jun 2017 --> Jun 2018 Initiation date: Nov 2012 --> Sep 2017
  • ||||||||||  lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
    Trial completion:  Long-Term Lamivudine Therapy for Chronic Hepatitis B (clinicaltrials.gov) -  Jun 30, 2017   
    P4,  N=50, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed
  • ||||||||||  ribavirin / Generic mfg.
    Trial completion:  Long-Term Therapy With Ribavirin for Chronic Hepatitis C (clinicaltrials.gov) -  Jun 30, 2017   
    P4,  N=50, Completed, 
    Recruiting --> Completed No longer recruiting --> Completed
  • ||||||||||  Trial completion:  Genetics of Hepatitis C Virus Infection (clinicaltrials.gov) -  Jun 30, 2017   
    P=N/A,  N=870, Completed, 
    No longer recruiting --> Completed Recruiting --> Completed
  • ||||||||||  TheraSphere (yttrium 90 microspheres) / Boston Scientific
    Enrollment change, Trial withdrawal, Surgery:  Radiolabeled Glass Beads (TheraSphere (clinicaltrials.gov) -  Jun 26, 2017   
    P2,  N=0, Withdrawn, 
    Trial primary completion date: Jul 2017 --> Jul 2018 N=500 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    Trial completion, Trial initiation date, Trial primary completion date, Metastases:  Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) -  Jun 14, 2017   
    P2,  N=40, Completed, 
    No longer recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008
  • ||||||||||  bortezomib / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date, Metastases:  Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder (clinicaltrials.gov) -  Jun 14, 2017   
    P2,  N=20, Terminated, 
    Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008 N=35 --> 20 | Completed --> Terminated | Trial primary completion date: Apr 2009 --> Aug 2008; The trial was discontinued early due to no confirmed partial responses.
  • ||||||||||  Trial primary completion date:  LIPROCES: Influence of Probiotics Administration Before Liver Resection in Liver Disease (clinicaltrials.gov) -  Jun 14, 2017   
    P=N/A,  N=64, Recruiting, 
    N=35 --> 20 | Completed --> Terminated | Trial primary completion date: Apr 2009 --> Aug 2008; The trial was discontinued early due to no confirmed partial responses. Trial primary completion date: Jan 2017 --> Jan 2018
  • ||||||||||  Trial primary completion date, IO biomarker:  The Pathogenesis of Hepatitis C Virus Vertical Transmission (clinicaltrials.gov) -  May 30, 2017   
    P=N/A,  N=50, Recruiting, 
    Recruiting --> Active, not recruiting | N=80 --> 60 Trial primary completion date: Jul 2017 --> Dec 2017
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Biomarker, Trial completion, Enrollment change, Trial primary completion date, Metastases:  Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) -  May 25, 2017   
    P1,  N=7, Completed, 
    Trial primary completion date: Jul 2017 --> Dec 2017 Active, not recruiting --> Completed | N=70 --> 7 | Trial primary completion date: Jun 2016 --> Nov 2010
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  INFECIR2: The INFECIR-2 Albumin Prevention Study (clinicaltrials.gov) -  May 18, 2017   
    P4,  N=136, Terminated, 
    No Longer Available --> Completed | Phase classification: PN/A --> P4 N=512 --> 136 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Dec 2016; Low recruitment rate and expiration of the study drug
  • ||||||||||  Enrollment change:  HepART-RCT: Hepatitis C Alcohol Reduction Treatment (clinicaltrials.gov) -  May 17, 2017   
    P=N/A,  N=279, Recruiting, 
    N=512 --> 136 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Dec 2016; Low recruitment rate and expiration of the study drug N=230 --> 279
  • ||||||||||  Enrollment closed, Trial primary completion date:  Gilead Sustained Virologic Response (SVR) Registry (clinicaltrials.gov) -  May 16, 2017   
    P=N/A,  N=6580, Active, not recruiting, 
    Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Jan 2020 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Jan 2020
  • ||||||||||  Tyzeka (telbivudine) / Novartis
    Enrollment closed, Combination therapy:  TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction (clinicaltrials.gov) -  May 16, 2017   
    P1/2,  N=120, Active, not recruiting, 
    Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Jan 2020 Enrolling by invitation --> Active, not recruiting
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  Immune Response to Hepatitis B Virus Booster Vaccination After 20-23 Years (clinicaltrials.gov) -  May 15, 2017   
    P=N/A,  N=9, Terminated, 
    Enrolling by invitation --> Active, not recruiting N=50 --> 9 | Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Dec 2015; Participants were not recruited promptly
  • ||||||||||  Taxoprexin (DHA-paclitaxel) / Daiichi Sankyo
    Enrollment change, Trial termination, Metastases:  Taxoprexin (clinicaltrials.gov) -  May 10, 2017   
    P2,  N=13, Terminated, 
    N=700 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2017 --> Jan 2017 N=60 --> 13 | Completed --> Terminated; Sponsor suspended development of the drug on September 3, 2008.